Drug
Imcgp100
Imcgp100: highest development phase Phase 2, developed by Immunocore. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Immunocore
Trials
| Drug | Phase | Indication |
|---|---|---|
| IMCgp100 NCT02889861 | Phase 2 | Malignant Melanoma |
| IMCgp100 NCT03070392 | Phase 2 | Uveal Melanoma |
| IMCgp100 NCT02570308 | Phase 1/2 | Uveal Melanoma |
| IMCgp100 NCT01211262 | Phase 1 | Malignant Melanoma |
Latest
No recent events.
Follow Imcgp100 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.